RG 7594
Alternative Names: RG-7594Latest Information Update: 19 Oct 2012
At a glance
- Originator Genentech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 16 Oct 2012 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
- 21 Jul 2011 Phase I development is ongoing in USA
- 22 Jul 2010 Phase-I clinical trials in Solid tumours in USA (unspecified route)